Literature DB >> 14627666

Silencing of CDKN1C (p57KIP2) is associated with hypomethylation at KvDMR1 in Beckwith-Wiedemann syndrome.

N Diaz-Meyer1, C D Day, K Khatod, E R Maher, W Cooper, W Reik, C Junien, G Graham, E Algar, V M Der Kaloustian, M J Higgins.   

Abstract

CONTEXT: Beckwith-Wiedemann syndrome (BWS) arises by several genetic and epigenetic mechanisms affecting the balance of imprinted gene expression in chromosome 11p15.5. The most frequent alteration associated with BWS is the absence of methylation at the maternal allele of KvDMR1, an intronic CpG island within the KCNQ1 gene. Targeted deletion of KvDMR1 suggests that this locus is an imprinting control region (ICR) that regulates multiple genes in 11p15.5. Cell culture based enhancer blocking assays indicate that KvDMR1 may function as a methylation modulated chromatin insulator and/or silencer.
OBJECTIVE: To determine the potential consequence of loss of methylation (LOM) at KvDMR1 in the development of BWS.
METHODS: The steady state levels of CDKN1C gene expression in fibroblast cells from normal individuals, and from persons with BWS who have LOM at KvDMR1, was determined by both real time quantitative polymerase chain reaction (qPCR) and ribonuclease protection assay (RPA). Methylation of the CDKN1C promoter region was assessed by Southern hybridisation using a methylation sensitive restriction endonuclease.
RESULTS: Both qPCR and RPA clearly demonstrated a marked decrease (86-93%) in the expression level of the CDKN1C gene in cells derived from patients with BWS, who had LOM at KvDMR1. Southern analysis indicated that downregulation of CDKN1C in these patients was not associated with hypermethylation at the presumptive CDKN1C promoter.
CONCLUSIONS: An epimutation at KvDMR1, the absence of maternal methylation, causes the aberrant silencing of CDKN1C, some 180 kb away on the maternal chromosome. Similar to mutations at this locus, this silencing may give rise to BWS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14627666      PMCID: PMC1735305          DOI: 10.1136/jmg.40.11.797

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  41 in total

1.  Dnmt3L and the establishment of maternal genomic imprints.

Authors:  D Bourc'his; G L Xu; C S Lin; B Bollman; T H Bestor
Journal:  Science       Date:  2001-11-22       Impact factor: 47.728

2.  Tumor development in the Beckwith-Wiedemann syndrome is associated with a variety of constitutional molecular 11p15 alterations including imprinting defects of KCNQ1OT1.

Authors:  R Weksberg; J Nishikawa; O Caluseriu; Y L Fei; C Shuman; C Wei; L Steele; J Cameron; A Smith; I Ambus; M Li; P N Ray; P Sadowski; J Squire
Journal:  Hum Mol Genet       Date:  2001-12-15       Impact factor: 6.150

3.  Loss of imprinting of insulin-like growth factor-II (IGF2) gene in distinguishing specific biologic subtypes of Wilms tumor.

Authors:  J D Ravenel; K W Broman; E J Perlman; E L Niemitz; T M Jayawardena; D W Bell; D A Haber; H Uejima; A P Feinberg
Journal:  J Natl Cancer Inst       Date:  2001-11-21       Impact factor: 13.506

4.  Epigenotype-phenotype correlations in Beckwith-Wiedemann syndrome.

Authors:  J R Engel; A Smallwood; A Harper; M J Higgins; M Oshimura; W Reik; P N Schofield; E R Maher
Journal:  J Med Genet       Date:  2000-12       Impact factor: 6.318

5.  Mice lacking a CDK inhibitor, p57Kip2, exhibit skeletal abnormalities and growth retardation.

Authors:  K Takahashi; K Nakayama; K Nakayama
Journal:  J Biochem       Date:  2000-01       Impact factor: 3.387

6.  Analysis of germline CDKN1C (p57KIP2) mutations in familial and sporadic Beckwith-Wiedemann syndrome (BWS) provides a novel genotype-phenotype correlation.

Authors:  W W Lam; I Hatada; S Ohishi; T Mukai; J A Joyce; T R Cole; D Donnai; W Reik; P N Schofield; E R Maher
Journal:  J Med Genet       Date:  1999-07       Impact factor: 6.318

7.  Targeted disruption of the human LIT1 locus defines a putative imprinting control element playing an essential role in Beckwith-Wiedemann syndrome.

Authors:  S Horike; K Mitsuya; M Meguro; N Kotobuki; A Kashiwagi; T Notsu; T C Schulz; Y Shirayoshi; M Oshimura
Journal:  Hum Mol Genet       Date:  2000-09-01       Impact factor: 6.150

8.  Increased tumour risk for BWS patients correlates with aberrant H19 and not KCNQ1OT1 methylation: occurrence of KCNQ1OT1 hypomethylation in familial cases of BWS.

Authors:  J Bliek; S M Maas; J M Ruijter; R C Hennekam; M Alders; A Westerveld; M M Mannens
Journal:  Hum Mol Genet       Date:  2001-03-01       Impact factor: 6.150

9.  Oppositely imprinted genes p57(Kip2) and igf2 interact in a mouse model for Beckwith-Wiedemann syndrome.

Authors:  T Caspary; M A Cleary; E J Perlman; P Zhang; S J Elledge; S M Tilghman
Journal:  Genes Dev       Date:  1999-12-01       Impact factor: 11.361

10.  Analysis of CDKN1C in Beckwith Wiedemann syndrome.

Authors:  E Algar; S Brickell; G Deeble; D Amor; P Smith
Journal:  Hum Mutat       Date:  2000       Impact factor: 4.878

View more
  45 in total

1.  MicroRNA-221 inhibits CDKN1C/p57 expression in human colorectal carcinoma.

Authors:  Kai Sun; Wei Wang; Jun-jie Zeng; Cheng-tang Wu; Shang-tong Lei; Guo-xin Li
Journal:  Acta Pharmacol Sin       Date:  2011-01-31       Impact factor: 6.150

2.  Maternal gametic transmission of translocations or inversions of human chromosome 11p15.5 results in regional DNA hypermethylation and downregulation of CDKN1C expression.

Authors:  Adam C Smith; Masako Suzuki; Reid Thompson; Sanaa Choufani; Michael J Higgins; Idy W Chiu; Jeremy A Squire; John M Greally; Rosanna Weksberg
Journal:  Genomics       Date:  2011-11-03       Impact factor: 5.736

3.  An antisense RNA regulates the bidirectional silencing property of the Kcnq1 imprinting control region.

Authors:  Noopur Thakur; Vijay Kumar Tiwari; Helene Thomassin; Radha Raman Pandey; Meena Kanduri; Anita Göndör; Thierry Grange; Rolf Ohlsson; Chandrasekhar Kanduri
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

4.  Oncogenic role of miR-483-3p at the IGF2/483 locus.

Authors:  Angelo Veronese; Laura Lupini; Jessica Consiglio; Rosa Visone; Manuela Ferracin; Francesca Fornari; Nicola Zanesi; Hansjuerg Alder; Gemma D'Elia; Laura Gramantieri; Luigi Bolondi; Giovanni Lanza; Patrizia Querzoli; Adriano Angioni; Carlo M Croce; Massimo Negrini
Journal:  Cancer Res       Date:  2010-04-13       Impact factor: 12.701

5.  Autonomous silencing of the imprinted Cdkn1c gene in stem cells.

Authors:  Michelle D Wood; Hitoshi Hiura; Simon J Tunster; Takahiro Arima; Jong-Yeon Shin; Michael J Higgins; Rosalind M John
Journal:  Epigenetics       Date:  2010-04-01       Impact factor: 4.528

6.  Developmental profile of H19 differentially methylated domain (DMD) deletion alleles reveals multiple roles of the DMD in regulating allelic expression and DNA methylation at the imprinted H19/Igf2 locus.

Authors:  Joanne L Thorvaldsen; Andrew M Fedoriw; Son Nguyen; Marisa S Bartolomei
Journal:  Mol Cell Biol       Date:  2006-02       Impact factor: 4.272

7.  Epigenetic and phenotypic consequences of a truncation disrupting the imprinted domain on distal mouse chromosome 7.

Authors:  Rosemary Oh; Rita Ho; Lynn Mar; Marina Gertsenstein; Jana Paderova; John Hsien; Jeremy A Squire; Michael J Higgins; Andras Nagy; Louis Lefebvre
Journal:  Mol Cell Biol       Date:  2007-11-26       Impact factor: 4.272

8.  Two distinct mechanisms of silencing by the KvDMR1 imprinting control region.

Authors:  Jong-Yeon Shin; Galina V Fitzpatrick; Michael J Higgins
Journal:  EMBO J       Date:  2007-12-13       Impact factor: 11.598

9.  Alternative mechanisms associated with silencing of CDKN1C in Beckwith-Wiedemann syndrome.

Authors:  N Diaz-Meyer; Y Yang; S N Sait; E R Maher; M J Higgins
Journal:  J Med Genet       Date:  2005-08       Impact factor: 6.318

10.  Targeted demethylation at the CDKN1C/p57 locus induces human β cell replication.

Authors:  Kristy Ou; Ming Yu; Nicholas G Moss; Yue J Wang; Amber W Wang; Son C Nguyen; Connie Jiang; Eseye Feleke; Vasumathi Kameswaran; Eric F Joyce; Ali Naji; Benjamin Glaser; Dana Avrahami; Klaus H Kaestner
Journal:  J Clin Invest       Date:  2018-11-26       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.